Compass Therapeutics Overview
- Founded
- 2014

- Status
- IPO Registration
- Employees
- 41

- Latest Deal Type
- IPO
- (Announced)
- Latest Deal Amount
- $50M

- Investors
- 29
Compass Therapeutics General Information
Description
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist, CTX-8371, and CTX-8573.
Contact Information
- 245 First Street
- 3rd Floor
- Cambridge, MA 02142
- United States
Compass Therapeutics Timeline
Compass Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
7. IPO | 19-Oct-2020 | $50M | 00000 | 00000 | Announced | Clinical Trials - Phase 1 |
6. Later Stage VC | 19-Jun-2020 | 0000 | 00000 | Completed | Clinical Trials - Phase 1 | |
5. Early Stage VC (Series A) | 12-Jul-2018 | 00000 | 00000 | Completed | Pre-Clinical Trials | |
4. Debt - General | 01-Mar-2018 | 0000 | 0000 | Completed | Clinical Trials - Phase 1 | |
3. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
2. Early Stage VC (Series A2) | 06-Sep-2016 | Completed | Clinical Trials - Phase 1 | |||
1. Early Stage VC (Series A1) | 02-Jun-2015 | Completed | Clinical Trials - Phase 1 |
Compass Therapeutics Comparisons
Industry
00000000
00000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialCompass Therapeutics Competitors (65)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
NexImmune | Venture Capital-Backed | Gaithersburg, MD | 00 | 000.00 | 00000000000 | 000.00 |
00000000 | Formerly VC-backed | Beltsville, MD | 00 | 00000 | 00000000 | 00000 |
0000000000 | Venture Capital-Backed | Abingdon, United Kingdom | 000 | 00000 | 00000000 | 00000 |
0000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
Compass Therapeutics Executive Team (12)
Compass Therapeutics Board Members (14)
Name | Representing | Role | Since |
---|---|---|---|
Bruce Steel | Self | Board Observer | 000 0000 |
Julie Sunderland | Biomatics Capital | Board Member | 000 0000 |
Philip Ferneau JD | Borealis Ventures | Board Member | 000 0000 |
Thomas Schuetz Ph.D | Compass Therapeutics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
Compass Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialCompass Therapeutics Investors (29)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Biobrit | Venture Capital | Minority | 000 0000 | 000000 0 | |
Consonance Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Limulus Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Adam Groff | Angel (individual) | Minority | 000 0000 | 000000 0 | |
Ashish Srimal | Angel (individual) | Minority | 000 0000 | 000000 0 |
Compass Therapeutics Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 00000000 | 23-Jun-2020 | 000000000000000000 | Other Capital Markets/Institutions | 000000 0000000 00.0 |